NCT04064190 - Vactosertib with Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition | Biotech Hunter

Timeline

Start Date

December 13, 2019

Primary Completion Date

December 30, 2023

Study Completion Date

December 30, 2024

Conditions

Urothelial Carcinoma RecurrentAdvanced Urothelial Carcinoma

Interventions

DRUG

Vactosertib(TEW-7197)/ Durvalumab

Vactosertib (PO) in combination with Durvalumab (IV) every 4 weeks

Trial Locations (2)

Roswell Park Comprehensive Cancer Center, Buffalo

University of California San Francisco, San Francisco